Renalytix plc (RNLXY) stock
RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)
Close on Oct 19, 2026Market cap $375.75MP/E –Yield –
Renalytix r&d expenses
Research and development expenses are spending on new products and technology.
Renalytix's R&D Expenses for the twelve months ending Sep 30, 2024 was $7.42M, down 44.3% year over year. For fiscal 2024 it was $9.29M, down 35.0% from the year before. The highest annual figure on record is $14.65M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $9.29M | -35.0% |
| FY2023 | Jun 30, 2023 | $14.30M | -2.4% |
| FY2022 | Jun 30, 2022 | $14.65M | +45.9% |
| FY2021 | Jun 30, 2021 | $10.04M | +119.9% |
| FY2020 | Jun 30, 2020 | $4.57M | +5.8% |
| FY2019 | Jun 30, 2019 | $4.32M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $921.00K | -67.0% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $1.06M | -67.5% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $2.22M | -43.8% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $3.23M | -3.0% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $2.79M | -25.8% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $3.27M | +24.5% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $3.94M | +1.4% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $3.33M | -19.5% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $3.76M | -6.0% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $2.63M | -3.7% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $3.89M | +25.2% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $4.13M | +67.9% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $4.00M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $2.73M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $3.10M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $2.46M | – |
See a number that looks wrong?